JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer

Inclusion Criteria:

* Voluntarily participate and sign a written informed consent form.
* Aged 18-75 years, regardless of sex.
* Histologically/cytologically confirmed HCC, or cirrhosis meeting the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria for HCC.
* No prior systemic therapy for HCC.
* At least one measurable lesion per RECIST v1.1 criteria.
* Child-Pugh liver function grade A or grade B with a score ≤7, and no history of hepatic encephalopathy.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.
* Expected survival ≥ 12 weeks.
* Adequate hematologic and end-organ function.
* Female participants of childbearing potential and male participants with female partners of childbearing potential must use a highly effective contraceptive method during the study and for at least 6 months after the last dose. Female participants of childbearing potential must have a negative blood HCG test within 7 days prior to study enrollment and must not be breastfeeding.

Exclusion Criteria:

* Concomitant with the following study disease states: Known intrahepatic cholangiocarcinoma (ICC) or mixed-type liver cancer, sarcomatoid hepatocellular carcinoma, and fibrolamellar carcinoma of the liver; Presence of HCC central nervous system metastasis.
* Prior treatment-related toxicity not recovered to ≤ CTCAE Grade 1.
* Severe infection at screening.
* Uncontrolled pericardial effusion, uncontrolled pleural effusion, or clinically apparent moderate or greater ascites at screening.

  -≥ Grade 3 (NCI-CTCAE v6.0) gastrointestinal or non-gastrointestinal fistula at screening.
* Severe unhealed wounds, active ulcers, or untreated fractures at screening.
* Severe cardiovascular or cerebrovascular disease:
* History of gastrointestinal bleeding within 6 months prior to the first dose, or definite tendency for gastrointestinal bleeding.
* Other obvious bleeding tendency or evidence of major coagulation disorders:
* Active autoimmune disease requiring systemic treatment within 2 years prior to the first dose.
* Malignancy other than HCC within 5 years prior to the first dose.
* Confirmed or suspected moderate-to-severe pulmonary disease severely affecting pulmonary function.
* Active tuberculosis.
* Co-infection with hepatitis B and hepatitis C.
* Known history of human immunodeficiency virus (HIV) infection, prior allogeneic stem cell or solid organ transplantation, or other immunodeficiency.
* Known history of severe allergy to any monoclonal antibody.
* Other factors that, in the investigator's judgment, may affect study results or lead to forced premature termination of the study.